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T-cell-rich B-cell lymphoma (TCRBCL) is considered a rare variant of aggressive B cell lymphoma 
characterized by few neoplastic B cells and a large reactive infiltrate with striking similarities to 
nodular lymphocyte predominant Hodgkin’s lymphoma.
A case of a 46 year old man referred with a 
weight loss, low grade pyrexia and two se
TCRBCL is described.
The clinical course was indeed aggressive because in spite of initial treatment with four cycles of 
CHOP  combination  chemotherapy,  followed  by  R+CHOP(x  6  cycles),  signs  of  tumor  re
growth/infiltration were frequently observed. Also, recurrent infection was frequent, troublesome 
and eventually became overwhelming resulting to the loss of the patient.
This case, being the first case of TCRBCL diagnosed by immunohistochemical confirmat
managed at this centre with R-CHOP, is presented to highlight the dilemma in making diagnosis, 
clinical challenges faced and rituximab therapy outcome especially in resource poor country. It will 
also serve to increase our index of suspicion and th
diagnosis of lymphoma.
Introduction: T-cell  Rich  B-Cell  Lymphoma 
(TCRBCL),  previously  considered  to  be  an 
extrapulmonary form  of  Lymphomatous 
Granulomatosus. It is generally considered to be a B 
cell  lymphoma  with  an  exuberant  benign  T  cell 
reaction.
1,2 It  was  first  described  as  a 
clinicopathological  entity  in  1972.
3 It’s  diagnosis  is 
based on histological triad of:  polymo
infiltrate composed of small lymphocytes, plasma cells 
and  variable  number  of  large  atypical  mononuclear 
cells; angitis due to transmural infiltration of arteries 
; Open Journal System 
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cell lymphoma (TCRBCL) is considered a rare variant of aggressive B cell lymphoma 
B cells and a large reactive infiltrate with striking similarities to 
nodular lymphocyte predominant Hodgkin’s lymphoma.
A case of a 46 year old man referred with a 5 months history of generalized lymphadenopathy, 
weight loss, low grade pyrexia and two separately reported lymph node histology consistent with 
The clinical course was indeed aggressive because in spite of initial treatment with four cycles of 
CHOP  combination  chemotherapy,  followed  by  R+CHOP(x  6  cycles),  signs  of  tumor  re
growth/infiltration were frequently observed. Also, recurrent infection was frequent, troublesome 
and eventually became overwhelming resulting to the loss of the patient.
This case, being the first case of TCRBCL diagnosed by immunohistochemical confirmat
CHOP, is presented to highlight the dilemma in making diagnosis, 
clinical challenges faced and rituximab therapy outcome especially in resource poor country. It will 
also serve to increase our index of suspicion and the need reinforce immunohistochemistry in the 
Cell  Lymphoma 
(TCRBCL),  previously  considered  to  be  an 
form  of  Lymphomatous 
Granulomatosus. It is generally considered to be a B 
cell  lymphoma  with  an  exuberant  benign  T  cell 
It  was  first  described  as  a 
It’s  diagnosis  is 
based on histological triad of:  polymorphic lymphoid 
infiltrate composed of small lymphocytes, plasma cells 
and  variable  number  of  large  atypical  mononuclear 
cells; angitis due to transmural infiltration of arteries 
and  veins  by  lymphocytes  (a  process  quite  different 
from  vasculitis  in  which  a
inflammatory cells are found with associated cell wall 
necrosis) and granulomatosis (central necrosis within 
the lymphoid nodules and not granuloma formation).
Therefore,  by  1990,  the  disease  was  viewed  as  an
extranodal,  angiocentric,  T  c
predilection for the lungs.
5
Flow  cytometric  immunophenotyping  and 
polymerase  chain  reaction  that  determine  T
receptor and immunoglobulin clonality is the hallmark 
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cell lymphoma (TCRBCL) is considered a rare variant of aggressive B cell lymphoma 
B cells and a large reactive infiltrate with striking similarities to 
5 months history of generalized lymphadenopathy, 
parately reported lymph node histology consistent with 
The clinical course was indeed aggressive because in spite of initial treatment with four cycles of 
CHOP  combination  chemotherapy,  followed  by  R+CHOP(x  6  cycles),  signs  of  tumor  re-
growth/infiltration were frequently observed. Also, recurrent infection was frequent, troublesome 
This case, being the first case of TCRBCL diagnosed by immunohistochemical confirmation and 
CHOP, is presented to highlight the dilemma in making diagnosis, 
clinical challenges faced and rituximab therapy outcome especially in resource poor country. It will 
e need reinforce immunohistochemistry in the 
and  veins  by  lymphocytes  (a  process  quite  different 
from  vasculitis  in  which  acute  and  chronic 
inflammatory cells are found with associated cell wall 
necrosis) and granulomatosis (central necrosis within 
the lymphoid nodules and not granuloma formation).
4
Therefore,  by  1990,  the  disease  was  viewed  as  an
extranodal,  angiocentric,  T  cell  lymphoma  with 
Flow  cytometric  immunophenotyping  and 
polymerase  chain  reaction  that  determine  T-cell 
receptor and immunoglobulin clonality is the hallmark Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
of diagnosis.
6 It is a rare subtype of lymphoma, with 
distinctive  histology  and  immunophenotype. 
Histologically  it  is  composed  of  ,  scattered  atypical 
large  neoplastic  cells  in  a  background  of  small 
lymphocytes and sometimes histiocytes. The large cells 
exhibited CD20+, CD79a+, EMA+, CD15- and CD30-
phenotype. On the other hand, the background small 
lymphocytes  were  CD3 and  CD45RO-positive.  Most 
of these background T cells express CD8 and TIA-1, 
while they are mostly CD57-negative. The histiocytic 
cells  are  CD68-positive;.  In-situ  hybridization  for 
EBER  1/2  show  negative  nuclear  signals. 
Immunoglobulin  heavy  chain  gene  rearrangement 
study usually reveal clonal pattern.
The  above features are  helpful in  delineating this 
entity  from  Nodular  Lymphocyte  predominant, 
Hodgkin  lymphoma(NLPHL),  reactive  lymphoid 
hyperplasia and lymphomatoid granulomatous.
Although LBCL lymphoma is the commonest type 
of  Non-Hodgkins  lymphoma  (NHL)  in  Ibadan, 
Nigeria;  diagnosis  of  TCRBCL  is  rare  and  has  not 
being reported in our sub region.
Case Presentation: The patient was a 46 year old man 
first  seen  in  February  2009  with  a  referral  from  a 
Private Facility in Lagos state. He presented with a 5 
month history of generalized lymphadenopathy, weight 
loss  and  low  grade  pyrexia.  Essential  findings  on 
physical  examination  included  bilateral  axillaries’, 
inguinal,  submandibular  lymphadenopathy,  size 
ranging from 2x2cm to 2x6cm; bilateral paedal oedema 
up to the groin, including scrotal and penile oedema, 
and  non- tender  generalized  sub-cutaneous  nodules. 
Examination of other systems was normal.
Preliminary  report  of  FNAC  received  by  the 
Institution  histopathologist  was  reactive  follicular 
hyperplasia.  But  subsequently  two  biopsy,  one  of 
subcutaneous  nodule  and  the  other  of  an  inguinal 
lymph node   were performed and  the histology pattern 
of  both  biopsy  was  consistent  with  Non-Hodgkin’s 
Lymphoma  of  T-cell  rich  diffuse  large  B-cell 
lymphoma (Figure 1) as certified by two independent 
pathologists.  This  diagnosis  was  quently 
subseconfirmed  by  immunohistochemistry showing  
reactive  cells were positive for CD3, CD5 and Bcl2 
while  the  neoplastic    cells  component  were  CD20 
positive;  CD10 and  cyclin D1  was  negative. All  the 
same, a third opinion was sought from the institution’s  
histopathologist , the histology report came much later
(because  of  logistic  reasons)  as  Hodgkin’s  Disease, 
Mixed Cellularity sub-type. As at that time of receiving 
this  third  opinion  report,  treatment  had  being 
commenced because of the poor state of the patient and  
patient  had  shown  very  good  response to 4 cycles of 
Figure  1:  Photomicrograph  showing  atypical  large  lymphoid  cells  in  a 
background containing normal small lymphocytes.
CHOP(Cyclophosphamide  Adriamycin,  Oncovin  and 
prednisolone) chemotherapy.
Further  investigations  included  Abdominal 
Ultrasound  which  reported  para-aortic  and  para-iliac 
lymphadenopathy,  chest    X-ray  showed  bilateral 
streaky  opacities  in  both  lung  fields  suggestive  of 
Pulmonary  tuberculosis  and  bone  marrow  aspiration 
showed  significant  (about  30%)  abnormal  lymphoid 
infiltration.  He  had  normal  biochemical  findings; 
retroviral screening and VDRL were negative
After well tolerated 4 cycles of CHOP, there was a 
total regression of the enlarged lymph nodes and other 
accompanying  signs.  Also,  FBC  and  biochemical 
investigations  were  within  normal.  At  this  juncture, 
chemotherapy was suspended for about 3 months and 
the waiting period was used to source for Rituximab. 
At the tail end of the third month, he had evidence of 
left  lobar  pneumonia  and  features  of  disease 
progression vis a vis recurrence of lymph nodes, re-
appearance of skin nodules at the trunk and elevated 
liver  enzymes.  The  pneumonia  responded  to 
combination  of  antibiotics.  When  he  subsequently 
commenced 21 day cycle of R-CHOP, of which he had 
six  cycles, there  was impressive evidence of disease 
remission.
However,  patient  developed  right  cervical 
lymphadenitis and abscess collection after the 5
th cycle 
of R-CHOP.  This was drained and the aspirate which 
was  sent  for  culture  yielded  Klebsiella,  sensitive  to 
Levofloxacin and which the patient had for 3 weeks.  
Three weeks after the resolution of the right cervical 
abscess he developed peri-anal abscess which had to be 
drained  by  the  surgeons.    Retroviral  screening  was 
negative but HBsAg was positive. He also developed 
numbness  of  both  feet  with  progressive  inability  to 
walk.  This  was  initially  thought  to  be  induced  by 
vincristine.Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
While  awaiting Neurologists  review  in  respect  of 
his  inability  to  walk  on  outpatient  basis,  he  was 
brought  acutely  ill  with  greenish tinge  jaundice, 
inability  to  walk,  recurrence  of  ishiorectal  abscess, 
distended abdomen with soft tender hepatomegaly of 
12cm  and  soft  tender  splenomegaly  of  8  cm.  While 
LFT was suggestive of obstructive jaundice; abdominal 
USS  confirmed  splenic  abscess  and  presence  of 
hepatomegaly. The result of CT – Abdomen showed 
evidence of para-spinal infiltration.
He was commenced on I.V. antibiotics (Ceftrazone 
and Flagyl) while exploring the possibility of draining 
the  abscess.  He  later  developed  haematochezia 
possibly due to acquired coagulation failure. He was 
supported  with  blood  and  blood  products.  Patient 
succumbed to the disease at this point.
Discussion: Our  experience  with  treating  lymphoma 
with R-CHOP is highly limited and in fact this index 
patient  being  reported  happened  to  be  the  second; 
partly because the cost of rituximab is out of rich for an 
average  patient  in  Nigeria  and  more  so  because 
immunohistochemistry has not fully taken its root in 
the  country.  This  dismal  deterioration  in  clinical 
outcome of this patient at the terminal phase gave a 
cause for concern especially when the best available 
has been offered for the patient. 
TCRBCL is said to be an uncommon morphologic 
variant of diffuse large B Cell Lymphoma in the REAL 
classification and the latest WHO classification.
8 It is 
characterized  histopathologically  by  less  than  10% 
malignant  B  cells  amid  a  majority  population  of 
reactive T-lymphocytes and histiocytes.
8 This makes 
the diagnosis of TCRBCL to be occasionally difficult 
in  that  it  is  a  close differential  diagnosis  of  other 
lymphoid  malignancies  such as  Hodgkins  lymphoma 
especially  Nodular  Lymphocyte  Predominant 
HD(NLPHD)  and  classic  HD  (cHD),  pleomorphic 
peripheral T-cell lymphoma and psudolymphoma.
9,10 In 
working towards making a diagnosis in this patient we 
encountered  similar  problem  in  that  after  we  had 
received 2 histological diagnoses from referral centre, 
we sought a third opinion of our home pathologist who 
in fact returned a diagnosis of HD mixed cellularity. 
Therapy  for  TCRLBCL  with  CHOP  was  however 
continued  because  there  was  already  a  good 
improvement to the treatment.  Apart from HD another 
very  close  differential  diagnosis  is  Peripheral  T  cell 
lymphoma. Therefore there is a great need for accurate 
diagnosis  of  this  disease  through careful  use  of 
immunohistochemistry.  A  specialized  private 
laboratory came to our aid in this respect. 
TCRBCL or T/HRBCL is an uncommon variant of 
DLBCL
4 and  it  represents  1-3%  of  all  DLBCL  in 
recent  series.
5,6,8 In  many  case  series  report 
published;
9,11,13 clinical presentation in advanced stage 
ranged  from  53-91%  while  frequency  of  splenic 
involvement ranged from 21-60%; frequency of liver 
involvement  and  that  of  bone  marrow  involvement 
ranged from 4-40%. Hepatosplenomegaly occurred at 
the  terminal  phase  of  this  patents  disease  while 
evidence of bone marrow infiltration was detected at 
diagnosis.
The reported mean age of occurrence of this disease 
is  40  years,
8,10,14,15,16 our  index  patient,  40  year  old 
male,  fits  into  documented  mean  age  at  diagnosis 
compared to 5
th decade of occurrence for DLBCL.
TRRBCL  is  recognized  to  have  both  nodal  and 
extra-nodal  presentation,  known  to  be  an  aggressive 
lymphoma that often presents as stage IV disease and 
with frequent bone marrow involvement.
9 This patient 
also presented in the late stage i.e. Ann arbor stage IV 
with  evidence  of  bone  marrow  involvement,  clinical 
and  radiological  evidence  of  pulmonary  infiltration; 
even though the liver and the spleen were not involved 
initially but  at the terminal stage both the liver and the 
spleen were involved. There  was pronounced weight 
loss  and  clinical evidence  of  pronounced  para-spinal 
infiltration which was later confirmed by CT scan.
There is a cause for concern in this patient who had 
established  diagnosis  of  TCRBCL  and  was  able  to 
afford  CHOP  chemotherapy  plus  rituximab  but 
terminally succumbed to the disease with evidence of 
multiple  organ  infiltration,  overwhelming  sepsis  and 
features of acquired coagulation failure.
This case report vividly highlights the difficulties of 
accurate  diagnosis  and  therapy  of  TCRBCL  in 
developing countries and also showed the probability 
of  high  risk  of  infectious  complications  by  modern 
immunotherapy performed under conditions of limited 
resources. There is therefore the need for a high index 
of suspicion, adequate infectious disease work-up and 
provision  of  comprehensive  immunohistochemistry 
facility  for  definitive  diagnosis  of  this  rare  form  of 
lymphoma. This  will ensure prompt targeted therapy 
and improved chance of survival  of this category of 
patients.
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